Financhill
Sell
45

OPRX Quote, Financials, Valuation and Earnings

Last price:
$9.49
Seasonality move :
8.73%
Day range:
$9.12 - $9.73
52-week range:
$3.78 - $14.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.85x
P/B ratio:
1.47x
Volume:
145.5K
Avg. volume:
226.8K
1-year change:
-12.15%
Market cap:
$172.5M
Revenue:
$92.1M
EPS (TTM):
-$1.10

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OPRX
OptimizeRx
$18.7M -$0.12 -5.1% -68.42% $10.83
ADUS
Addus HomeCare
$339.9M $1.33 21.63% 34.21% $135.70
AMED
Amedisys
$596.5M $1.11 4.11% 40.38% $96.86
HCAT
Health Catalyst
$79.2M $0.00 5.92% -99.77% $8.23
HUM
Humana
$32.2B $10.07 7.62% 6.74% $309.40
OPCH
Option Care Health
$1.3B $0.35 10.25% 32.25% $38.56
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OPRX
OptimizeRx
$9.33 $10.83 $172.5M -- $0.00 0% 1.85x
ADUS
Addus HomeCare
$108.62 $135.70 $2B 24.52x $0.00 0% 1.60x
AMED
Amedisys
$96.11 $96.86 $3.2B 35.46x $0.00 0% 1.34x
HCAT
Health Catalyst
$4.07 $8.23 $285.8M -- $0.00 0% 0.80x
HUM
Humana
$251.77 $309.40 $30.4B 17.81x $0.89 1.41% 0.25x
OPCH
Option Care Health
$32.74 $38.56 $5.4B 26.40x $0.00 0% 1.08x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OPRX
OptimizeRx
21.91% -2.555 36.59% 2.77x
ADUS
Addus HomeCare
16.64% 0.970 11.06% 1.57x
AMED
Amedisys
23.6% -0.140 12.01% 1.23x
HCAT
Health Catalyst
51.15% 1.824 84.45% 1.38x
HUM
Humana
42.84% 2.380 41.58% 1.50x
OPCH
Option Care Health
45.12% 0.749 19.41% 0.91x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OPRX
OptimizeRx
$22M $3.6M -12.93% -16.71% 11.67% $78K
ADUS
Addus HomeCare
$107.7M $30.5M 7.78% 8.66% 9.04% $18.9M
AMED
Amedisys
$260.7M $60.1M 5.72% 7.55% 16.41% -$5.1M
HCAT
Health Catalyst
$34.7M -$17.5M -10.81% -19.29% -16.02% -$8.4M
HUM
Humana
-- -- 5.74% 10.08% 5.76% $236M
OPCH
Option Care Health
$263.1M $79.2M 8.53% 15.22% 5.76% -$16.6M

OptimizeRx vs. Competitors

  • Which has Higher Returns OPRX or ADUS?

    Addus HomeCare has a net margin of -0.24% compared to OptimizeRx's net margin of 6.29%. OptimizeRx's return on equity of -16.71% beat Addus HomeCare's return on equity of 8.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    OPRX
    OptimizeRx
    68.15% -- $149.8M
    ADUS
    Addus HomeCare
    31.89% $1.16 $1.2B
  • What do Analysts Say About OPRX or ADUS?

    OptimizeRx has a consensus price target of $10.83, signalling upside risk potential of 16.11%. On the other hand Addus HomeCare has an analysts' consensus of $135.70 which suggests that it could grow by 24.93%. Given that Addus HomeCare has higher upside potential than OptimizeRx, analysts believe Addus HomeCare is more attractive than OptimizeRx.

    Company Buy Ratings Hold Ratings Sell Ratings
    OPRX
    OptimizeRx
    4 1 0
    ADUS
    Addus HomeCare
    7 0 0
  • Is OPRX or ADUS More Risky?

    OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Addus HomeCare has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.958%.

  • Which is a Better Dividend Stock OPRX or ADUS?

    OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addus HomeCare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Addus HomeCare pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OPRX or ADUS?

    OptimizeRx quarterly revenues are $32.3M, which are smaller than Addus HomeCare quarterly revenues of $337.7M. OptimizeRx's net income of -$78K is lower than Addus HomeCare's net income of $21.2M. Notably, OptimizeRx's price-to-earnings ratio is -- while Addus HomeCare's PE ratio is 24.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.85x versus 1.60x for Addus HomeCare. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OPRX
    OptimizeRx
    1.85x -- $32.3M -$78K
    ADUS
    Addus HomeCare
    1.60x 24.52x $337.7M $21.2M
  • Which has Higher Returns OPRX or AMED?

    Amedisys has a net margin of -0.24% compared to OptimizeRx's net margin of 10.26%. OptimizeRx's return on equity of -16.71% beat Amedisys's return on equity of 7.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    OPRX
    OptimizeRx
    68.15% -- $149.8M
    AMED
    Amedisys
    43.84% $1.84 $1.6B
  • What do Analysts Say About OPRX or AMED?

    OptimizeRx has a consensus price target of $10.83, signalling upside risk potential of 16.11%. On the other hand Amedisys has an analysts' consensus of $96.86 which suggests that it could grow by 0.78%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    OPRX
    OptimizeRx
    4 1 0
    AMED
    Amedisys
    0 9 1
  • Is OPRX or AMED More Risky?

    OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Amedisys has a beta of 0.964, suggesting its less volatile than the S&P 500 by 3.612%.

  • Which is a Better Dividend Stock OPRX or AMED?

    OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OPRX or AMED?

    OptimizeRx quarterly revenues are $32.3M, which are smaller than Amedisys quarterly revenues of $594.8M. OptimizeRx's net income of -$78K is lower than Amedisys's net income of $61M. Notably, OptimizeRx's price-to-earnings ratio is -- while Amedisys's PE ratio is 35.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.85x versus 1.34x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OPRX
    OptimizeRx
    1.85x -- $32.3M -$78K
    AMED
    Amedisys
    1.34x 35.46x $594.8M $61M
  • Which has Higher Returns OPRX or HCAT?

    Health Catalyst has a net margin of -0.24% compared to OptimizeRx's net margin of -25.97%. OptimizeRx's return on equity of -16.71% beat Health Catalyst's return on equity of -19.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    OPRX
    OptimizeRx
    68.15% -- $149.8M
    HCAT
    Health Catalyst
    43.58% -$0.33 $747.6M
  • What do Analysts Say About OPRX or HCAT?

    OptimizeRx has a consensus price target of $10.83, signalling upside risk potential of 16.11%. On the other hand Health Catalyst has an analysts' consensus of $8.23 which suggests that it could grow by 102.14%. Given that Health Catalyst has higher upside potential than OptimizeRx, analysts believe Health Catalyst is more attractive than OptimizeRx.

    Company Buy Ratings Hold Ratings Sell Ratings
    OPRX
    OptimizeRx
    4 1 0
    HCAT
    Health Catalyst
    7 4 0
  • Is OPRX or HCAT More Risky?

    OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Health Catalyst has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.873%.

  • Which is a Better Dividend Stock OPRX or HCAT?

    OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OPRX or HCAT?

    OptimizeRx quarterly revenues are $32.3M, which are smaller than Health Catalyst quarterly revenues of $79.6M. OptimizeRx's net income of -$78K is higher than Health Catalyst's net income of -$20.7M. Notably, OptimizeRx's price-to-earnings ratio is -- while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.85x versus 0.80x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OPRX
    OptimizeRx
    1.85x -- $32.3M -$78K
    HCAT
    Health Catalyst
    0.80x -- $79.6M -$20.7M
  • Which has Higher Returns OPRX or HUM?

    Humana has a net margin of -0.24% compared to OptimizeRx's net margin of 3.87%. OptimizeRx's return on equity of -16.71% beat Humana's return on equity of 10.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    OPRX
    OptimizeRx
    68.15% -- $149.8M
    HUM
    Humana
    -- $10.30 $31.1B
  • What do Analysts Say About OPRX or HUM?

    OptimizeRx has a consensus price target of $10.83, signalling upside risk potential of 16.11%. On the other hand Humana has an analysts' consensus of $309.40 which suggests that it could grow by 22.89%. Given that Humana has higher upside potential than OptimizeRx, analysts believe Humana is more attractive than OptimizeRx.

    Company Buy Ratings Hold Ratings Sell Ratings
    OPRX
    OptimizeRx
    4 1 0
    HUM
    Humana
    6 17 0
  • Is OPRX or HUM More Risky?

    OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Humana has a beta of 0.494, suggesting its less volatile than the S&P 500 by 50.63%.

  • Which is a Better Dividend Stock OPRX or HUM?

    OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana offers a yield of 1.41% to investors and pays a quarterly dividend of $0.89 per share. OptimizeRx pays -- of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios OPRX or HUM?

    OptimizeRx quarterly revenues are $32.3M, which are smaller than Humana quarterly revenues of $32.1B. OptimizeRx's net income of -$78K is lower than Humana's net income of $1.2B. Notably, OptimizeRx's price-to-earnings ratio is -- while Humana's PE ratio is 17.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.85x versus 0.25x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OPRX
    OptimizeRx
    1.85x -- $32.3M -$78K
    HUM
    Humana
    0.25x 17.81x $32.1B $1.2B
  • Which has Higher Returns OPRX or OPCH?

    Option Care Health has a net margin of -0.24% compared to OptimizeRx's net margin of 3.51%. OptimizeRx's return on equity of -16.71% beat Option Care Health's return on equity of 15.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    OPRX
    OptimizeRx
    68.15% -- $149.8M
    OPCH
    Option Care Health
    19.73% $0.28 $2.5B
  • What do Analysts Say About OPRX or OPCH?

    OptimizeRx has a consensus price target of $10.83, signalling upside risk potential of 16.11%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 17.76%. Given that Option Care Health has higher upside potential than OptimizeRx, analysts believe Option Care Health is more attractive than OptimizeRx.

    Company Buy Ratings Hold Ratings Sell Ratings
    OPRX
    OptimizeRx
    4 1 0
    OPCH
    Option Care Health
    6 1 0
  • Is OPRX or OPCH More Risky?

    OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Option Care Health has a beta of 0.763, suggesting its less volatile than the S&P 500 by 23.686%.

  • Which is a Better Dividend Stock OPRX or OPCH?

    OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OPRX or OPCH?

    OptimizeRx quarterly revenues are $32.3M, which are smaller than Option Care Health quarterly revenues of $1.3B. OptimizeRx's net income of -$78K is lower than Option Care Health's net income of $46.7M. Notably, OptimizeRx's price-to-earnings ratio is -- while Option Care Health's PE ratio is 26.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.85x versus 1.08x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OPRX
    OptimizeRx
    1.85x -- $32.3M -$78K
    OPCH
    Option Care Health
    1.08x 26.40x $1.3B $46.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Is it Safe to Invest in Google With OpenAI Threats?
Is it Safe to Invest in Google With OpenAI Threats?

For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…

Is Broadcom Stock a Millionaire Maker?
Is Broadcom Stock a Millionaire Maker?

Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
60
RGC alert for May 7

Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.

Buy
77
FARO alert for May 7

Faro Technologies [FARO] is down 0% over the past day.

Buy
53
SRPT alert for May 7

Sarepta Therapeutics [SRPT] is down 21.54% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock